TABLE 2.

In vitro susceptibilities of Candida spp. and C. neoformans isolates from North America, Europe, and Latin America to seven antifungal agents (SENTRY Program, 2003)

Species (no. of isolates tested in North America, Europe, and Latin America) and drugMIC (μg/ml) or % of isolates susceptiblea
North AmericaEuropeLatin America
50%90%%S50%90%%S50%90%%S
All Candida spp. (784, 336, 277)
    Amphotericin B111111
    5-FCb0.12295.90.25892.60.12196.8
    Fluconazole0.51686.40.51689.30.5893.5
    Ketoconazole0.01610.0160.50.030.5
    Itraconazole0.12157.10.12159.50.25146.6
    Voriconazole0.0160.25≤0.0080.250.030.25
    Ravuconazole≤0.0080.5≤0.0080.250.030.25
C. albicans (404, 175, 101)
    Amphotericin B111111
    5-FC0.25297.00.120.598.90.12299.0
    Fluconazole0.250.599.00.250.5100.0≤0.120.5100.0
    Ketoconazole≤0.0080.016≤0.0080.016≤0.0080.03
    Itraconazole0.060.1292.80.060.1294.30.060.1290.1
    Voriconazole≤0.008≤0.008≤0.008≤0.008≤0.0080.016
    Ravuconazole≤0.008≤0.008≤0.008≤0.008≤0.008≤0.008
C. parapsilosis (122, 55, 65)
    Amphotericin B111111
    5-FC0.120.5100.00.250.5100.00.120.25100.0
    Fluconazole1297.512100.018100.0
    Ketoconazole0.120.250.120.250.120.5
    Itraconazole0.250.537.70.250.530.90.250.524.6
    Voriconazole0.030.120.030.060.030.12
    Ravuconazole0.030.120.030.060.030.12
C. glabrata (167, 43, 30)
    Amphotericin B121112
    5-FC0.060.12100.00.120.12100.00.120.12100.0
    Fluconazole86452.1812853.586450.0
    Ketoconazole0.520.5212
    Itraconazole120.0120.0140.0
    Voriconazole0.2510.2520.51
    Ravuconazole0.2510.2510.52
C. tropicalis (59, 34, 59)
    Amphotericin B111111
    5-FC0.250.594.90.25>6476.50.250.593.2
    Fluconazole1296.61497.112100.0
    Ketoconazole0.030.120.030.120.060.12
    Itraconazole0.250.539.00.250.529.40.250.527.1
    Voriconazole0.030.120.060.250.060.12
    Ravuconazole0.030.120.030.250.030.12
C. neoformansc (23, 3, 27)
    Amphotericin B11111
    5-FC8168816
    Fluconazole163281632
    Ketoconazole0.510.50.51
    Itraconazole0.510.50.51
    Voriconazole0.120.50.120.250.25
    Ravuconazole0.120.50.120.120.25
  • a The breakpoint criteria are those of the NCCLS/CLSI (7); %S, percent susceptible.

  • b 5-FC, 5-fluorocytosine.

  • c Breakpoint criteria have not been established for cryptococcal organisms (7).